Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

HCV."

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease, is the focus of a rapidly evolving treatment landscape. Approximately 150 million people are infected with hepatitis C worldwide – including approximately 3.2 million people in the United States – and 350,000 people per year die from the disease globally. When left untreated, hepatitis C can cause significant damage to the liver including cirrhosis. Additionally, hepatitis C may increase the risk of developing complications from cirrhosis, which may include liver failure.

About Simeprevir
Simeprevir (TMC435) is an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and its affiliated companies and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the viral protease enzyme that enables the hepatitis C virus to replicate in host cells.

Janssen is responsible for the global clinical development of simeprevir and has acquired exclusive, worldwide marketing rights, except for the Nordic countries. Medivir AB will retain marketing rights for simeprevir in these Nordic countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved on September 27, 2013 in Japan for the treatment of genotype 1 hepatitis C and a Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C.

Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action. To date, more than 3,700 patients have been tre
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... of new products for oncology supportive care, announced that ... has been featured in an article on OncLive.com titled, ... Head and Neck Cancers."  Dr. Steve Sonis , ... the growing demand seen in the oncology community for ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
(Date:7/30/2014)... 2014   Medical Equipment Solutions, Corp. are ... Department of Defense (US Army) contract valued at over ... MRI diagnostic machine and technical support staffing. As an ... Small Business Administration (SBA), Medical Equipment is proud to ... latest medical diagnostic equipment. The SBA 8-A certification is ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... and Glycemic Control Benefits of PistachiosNEW ORLEANS, April 22 ... The little green nuts may do more for ... snack food choices, according to research presented this week ... from UCLA and the University of ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) announced today ... BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment ... IVA), or Morquio A Syndrome. The company expects ... 2010. "We plan to leverage our clinical, manufacturing ...
Cached Medicine Technology:Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity 2Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity 3Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity 4BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 2BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 3BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome 4
(Date:7/30/2014)... education in sub-Saharan Africa is being revitalized and ... increasing enrollment, broadening curricula, upgrading Internet access and ... , In the first substantial publication by participants ... (MEPI), more than 225 authors detailed progress being ... in a supplement being published today by the ...
(Date:7/30/2014)... to artemisinin, the main drug to treat malaria, ... Plasmodium falciparum ( P. falciparum ) ... caused by a genetic mutation in the parasites. ... opposed to a standard three-day coursehas proved highly ... findings published today in the New England ...
(Date:7/30/2014)... By Steven Reinberg ... -- Each year in the United States, at least 2,000 ... health officials said Wednesday. Heat waves, heat stroke or ... deaths reported between 2006 and 2010, according to the U.S. ... hypothermia -- a severe loss of body heat -- accounted ...
(Date:7/30/2014)... -- It can happen in an instant: A small child ... and gets critically injured when the furniture tips over. ... around their homes and imagine what could tip over, fall ... than it becoming a reality," Dr. Alex Rosenau, president of ... news release. Between 2009 and 2011, roughly 43,000 people ...
(Date:7/30/2014)... SF Cable, distributor of the highest ... on the internet with guaranteed customer satisfaction announces the ... two colors. These lightning cords are MFI certified to ... quality SF Cable Lightning to USB Cables ... faster charging and syncing. Compatible with the iPhone 5S/5C/5 ...
Breaking Medicine News(10 mins):Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:Tip-Over Furniture Can Kill Kids 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2
... light of womens so-called moodiness, often jokingly attributing it ... fact, mood disorders are a serious and pervasive health ... 1.5 to 3 times more likely to suffer from ... a newly published study, womens health experts from the ...
... conference hosted by New York,Attorney General Andrew Cuomo ... N.Y., Dec. 12 The following is a,statement ... "The American Medical Association is committed to improving ... and compare physician,performance represent potential quality improvement tools ...
... an innovative,leader in the development and marketing of products ... Bryce T. IntVeld has,joined the Company as Vice President ... and oversee the establishment and expansion,of sales activities in ... have Bryce as a member of our executive management,team," ...
... a vaccine to,prevent shingles was approved for use in ... people age 60 and older who,previously had chickenpox. But ... shingles primarily affects adults with weakened immune,systems -- have ... vaccine. This uncertainty prompted a group of researchers led ...
... Long Term Care,Pharmacy Alliance (LTCPA), which has been ... serve nursing home residents since 2001,announced today that ... pharmacy,companies that serve most of the nation,s 1.8 ... "LTCPA represents highly specialized pharmacies which specifically,serve nursing ...
... Yesterday, the U.S. Court of,Appeals for the ... (DEA) 2006 revocation of Wedgewood Pharmacy,s registration,to dispense ... since it first was issued., The ruling ... decision and the DEA,s denial of Wedgewood,s petition ...
Cached Medicine News:Health News:Experts call for better research into link between women's hormones and mood disorders 2Health News:AMA Commends Independent Health for Joining Industry Shift on Physician Performance Measurement 2Health News:Scient'x USA Strengthens Leadership Team With Appointment of Bryce IntVeld as Vice President of Sales 2Health News:Mayo Clinic Proceedings Article Offers New Data About the Impact of the Shingles Virus on Healthy Adults 2Health News:Mayo Clinic Proceedings Article Offers New Data About the Impact of the Shingles Virus on Healthy Adults 3Health News:Long Term Care Pharmacy Alliance Expands Membership; Members Now Serve Most of the Nation's Nursing Home Residents 2Health News:Wedgewood Pharmacy: U.S. Court of Appeals Vacates DEA Action 2Health News:Wedgewood Pharmacy: U.S. Court of Appeals Vacates DEA Action 3Health News:Wedgewood Pharmacy: U.S. Court of Appeals Vacates DEA Action 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: